Mesalazine combined with golden bifid for treatment of patients with ulcerative colitis: Effect on inflammatory response and anorectal motility

World Chinese Journal of Digestology

Volumn 26, Issue 10, 2018, Pages 594-600

  Fang, Wei Bing ^a   Cai, Qing Feng ^b  

^a First People s Hospital of Chun an County   (China)

^b TAIZHOU HOSPITAL OF ZHEJIANG PROVINCE   (China)

Author keywords

Cytokines; Disease activity index; Golden bifid; Mesalazine; Ulcerative colitis

Indexed keywords

CYTOKINE; GOLDEN BIFID; INTERLEUKIN 10; INTERLEUKIN 18; MESALAZINE; PROBIOTIC AGENT; SOLUBLE INTERLEUKIN 2 RECEPTOR; TUMOR NECROSIS FACTOR;

ANORECTAL MOTILITY; ANUS CONTINENCE; ARTICLE; BLOOD LEVEL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DEFECATION; DISEASE ACTIVITY; DRUG EFFECT; DRUG EFFICACY; FOLLOW UP; GASTROINTESTINAL MOTILITY; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; PAIN THRESHOLD; ULCERATIVE COLITIS;

EID: 85045124961     PISSN: 10093079     EISSN: None     Source Type: Journal    
DOI: 10.11569/wcjd.v26.i10.594     Document Type: Article

References (4)

1. Pica R, Cassieri C, Cocco A, Zippi M, Marcheggiano A, De Nitto D, Avallone EV, Crispino P, Occhigrossi G, Paoluzi P. A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis. Dig Liver Dis 2015; 47: 933-937 [PMID: 26391602 DOI: 10.1016/j.dld.2015.07.011]
2. Karner M, Kocjan A, Stein J, Schreiber S, von Boyen G, Uebel P, Schmidt C, Kupcinskas L, Dina I, Zuelch F, Keilhauer G, Stremmel W. First multicenter study of modified release phosphatidylcholine “LT-02” in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses. Am J Gastroenterol 2014; 109: 1041-1051 [PMID: 24796768 DOI: 10.1038/ajg.2014.104]
3. Probert CS, Dignass AU, Lindgren S, Oudkerk Pool M, Marteau P. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life. J Crohns Colitis 2014; 8: 200-207 [PMID: 24012063 DOI: 10.1016/j.crohns.2013.08.007]
4. Walmsley RS. Comment on an optimized patient-reported ulcerative colitis disease activity measure derived from the mayo score and the simple clinical colitis activity index. Inflamm Bowel Dis 2014; 20: E25-E26 [PMID: 25374290 DOI: 10.1097/MIB.0000000000000248]